Last reviewed · How we verify
Mild to moderate ulcerative colitis
Approved treatments
- Infliximab [infliximab biosimilar 3] · Pfizer
Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Mild to moderate ulcerative colitis patent landscape — cliff calendar, originator estates, attackable patents
- Mild to moderate ulcerative colitis treatment landscape brief
- Mild to moderate ulcerative colitis treatment updates RSS
Frequently asked questions about Mild to moderate ulcerative colitis
What drugs treat Mild to moderate ulcerative colitis?
Tracked treatments include Infliximab [infliximab biosimilar 3].
What is the treatment for Mild to moderate ulcerative colitis?
Standard treatment for Mild to moderate ulcerative colitis includes Infliximab [infliximab biosimilar 3]. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Mild to moderate ulcerative colitis patent cliff · Mild to moderate ulcerative colitis CI report
- Treatment: Infliximab [infliximab biosimilar 3] · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing